Journal of Diabetes and Its Complications
Volume 25, Issue 6 , Pages 368-370 , November 2011

High-sensitivity C-reactive protein: a novel cardiovascular risk predictor in type 2 diabetics with normal lipid profile

Received 9 December 2010 ,Revised 27 August 2011 ,Accepted 7 October 2011.

References 

  1. Ahmed A, Shantha GP, Agarwal G, Senthil N, Paunikar N, Sudhakar MK. Prevalence of microvascular complications in metabolic syndrome in comparison to type II DM. J Indian Med Assoc. 2008;106:571–574, 578
  2. Ajay K. Coronary artery disease & diabetes. Cardiology Today. 2001;4:221–224
  3. Armani A, Becker RC. The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: Part II. American Heart Journal. 2005;149:977–983
  4. Braunwald E. Shattuck Lecturer. Cardiovascular medicine at the turn of the millennium. New England Journal of Medicine. 1997;327:1360–1369
  5. Dullaart RP, deVries R, Sluiter WJ, Voorbij HA. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus. Clinical Endocrinology (OXF). 2009;70(2):221–226
  6. Gokulakrishnan K, Deepa R, Mohan V. Association of high sensitivity C-reactive protein (hsCRP) and tumour necrosis factor-alpha (TNF-alpha) with carotid intimal medial thickness in subjects with different grades of glucose intolerance—the Chennai Urban Rural Epidemiology Study (CURES-31). Clin Biochem. 2008;41(7-8):480–485[Epub 2008 Feb 2]
  7. Holly, J. L. (ND) C-reactive protein & your heart. Southeast Texas Medical Associates, L.L.P. (SETMA).
  8. Hsieh MC, Tien KJ, Chang SJ, Perng DS, Hsiao JY, Chen YW, et al. High-sensitivity C-reactive protein and silent myocardial ischemia in Chinese with type 2 diabetes mellitus. Metabolism. 2008;57:1533–1538
  9. Mahajan A, Tabassum R, Chavali S, Dwivedi OP, Bharadwaj M, Tandon N, et al. High-sensitivity C-reactive protein levels and type 2 diabetes in urban north Indians. The Journal of Clinical Endocrinology & Metabolism. 2009;94(6):2123–2127
  10. Mitra B, Panja M. High sensitive C-reactive protein: a novel biochemical marker and its role in coronary artery disease. The Journal of the Association of Physicians of India. 2005;53:25–30
  11. Nair KS, Bigelow ML, Asmann YW, Chow LS, Schimke JMC, Klaus KA, et al. Asian Indians have enhanced skeletal muscle mitochondrial capacity to produce ATP in association with severe insulin resistance. Diabetes. 2008;57:1166–1175
  12. Pfutzner A, Forst T. High sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technology & Therapeutics. 2006;8(1):28–36
  13. Pu LJ, Lu L, Xu XW, Zhang RY, Zhang Q, Zhang JS, et al. Value of serum glycated albumin & high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovascular Diabetology. 2006;5:27
  14. Rani HS, Madhvi G, Rao VR, Sahay BK, Jyothy A. Risk factors for coronary heart disease in type II DM. Indian Journal of Clinical Biochemistry. 2005;20(2):75–80
  15. Ridkar PM. Clinical application of C-reactive protein for cardiovascular disease detection & prevention. Circulation. 2003;107:363
  16. Ridkar PM, Rifai N, Rose L, et al. Comparison of CRP & LDL cholesterol level in prediction of first cardiovascular event. The New England Journal of Medicine. 2002;347:1557–1565
  17. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. The New England Journal of Medicine. 2000;342(12):836–843
  18. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767–1772
  19. Sharma SB, Garg S, Veerwal A, Dwivedi S. Hs-CRP and oxidative stress in young cad patients: a pilot study. Indian Journal of Clinical Biochemistry. 2008;23(4):334–336
  20. Stehouwer C, Gall M, Twisk J, et al. Increased urinary albumin excretion, endothelial dysfunction & chronic low grade inflammation in type II DM: progressive interrelated & independently associated with risk of death. Diabetes. 2002;51:1157–1165
  21. Tiong AY, Brieger D. Inflammation and coronary artery disease. Am Heart J. 2005;150:11–18
  22. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2030. Diabetes Care. 2004;27:1047–1053

PII: S1056-8727(11)00123-1

doi: 10.1016/j.jdiacomp.2011.10.001

Journal of Diabetes and Its Complications
Volume 25, Issue 6 , Pages 368-370 , November 2011

Article Tools